Drugs / GSK223192A
last change Jul 2011 re-read 2 minutes ago

GSK223192A

Vaccine

Developed for
hepatitis B virus infection
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00805389 Dec 2008 → Sep 2010 hepatitis B virus infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK223192A ClinicalTrials.gov intervention name — accepted as the source's own label NCT00805389
Modality Vaccine “GSK Biologicals' Hepatitis B vaccines (GSK223192A)” NCT00805389